Compare IDEXX Laboratories, Inc. (IDXX) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs McCormick & Company, Incorporated — how do they compare? IDEXX Laboratories, Inc. trades at $569.6 (market cap $46.22B), while McCormick & Company, Incorporated trades at $52.9 (market cap $14.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.3× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MKC | |
|---|---|---|
Market Cap | $46.22B | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $72.26 |
52-Week Low | $526.44 | $45.60 |
Enterprise Value | $47.12B | $18.82B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
McCormick & Company (MKC) trades at $53.10, down slightly by 0.06% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion Unilever Foods merger planned for 2027, driving positive sentiment and a consensus price target of $59.67.
MKC presents a compelling investment case with undervalued metrics and strategic growth from the Unilever deal, though risks include integration challenges and soft consumer volumes. Analysts are mixed but lean bullish, with 36.67% buy ratings. The stock offers a solid dividend and upside potential, but investors should monitor merger execution and volume trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
